Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Diversify Advisory Services LLC slashed its Arcturus holding by 88.5%, selling 115,500 shares and retaining 15,000 shares (about $92,000) at the end of the quarter.
• Arcturus reported Q results that missed expectations — EPS ($1.03) vs. ($0.92) expected and revenue $7.2M vs. $14.32M expected — and the company shows negative margins with analysts forecasting -2.22 EPS for the year.
• Analysts hold a consensus rating of “Moderate Buy” with a $29.50 target, though several firms have sharply cut price targets (e.g., Citigroup to $21, Piper Sandler to $25), reflecting mixed sentiment.

Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the biotechnology company's stock after selling 115,500 shares during the period. Diversify Advisory Services LLC owned 0.05% of Arcturus Therapeutics worth $92,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Osaic Holdings Inc. raised its stake in Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock worth $28,000 after buying an additional 738 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock worth $54,000 after buying an additional 2,586 shares in the last quarter. Strs Ohio bought a new position in Arcturus Therapeutics in the first quarter worth about $89,000. Byrne Asset Management LLC raised its stake in Arcturus Therapeutics by 4,412.5% in the fourth quarter. Byrne Asset Management LLC now owns 18,050 shares of the biotechnology company's stock worth $111,000 after buying an additional 17,650 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA bought a new position in Arcturus Therapeutics in the third quarter worth about $111,000. 94.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Citigroup decreased their price target on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, March 5th. B. Riley Financial initiated coverage on shares of Arcturus Therapeutics in a report on Wednesday, March 18th. They issued a "buy" rating and a $22.00 price objective on the stock. Piper Sandler cut their price objective on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, March 4th. Roth Mkm initiated coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They issued a "buy" rating and a $20.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.50.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $8.84 on Friday. The stock has a market cap of $251.23 million, a PE ratio of -3.71 and a beta of 2.44. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $24.17. The firm's 50-day simple moving average is $7.59 and its two-hundred day simple moving average is $9.08.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.11). The business had revenue of $7.20 million during the quarter, compared to analysts' expectations of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. Equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.